Clinical Implications of Cognitive Disturbances in Major Depression
This CE activity is based on the slides and lectures presented by the faculty at the Psych Congress 1-Day Regional meeting in Anaheim, California on Saturday, November 8, 2014.
Michael J. Ostacher, MD, MPH, MMSc
Professor of Psychiatry and Behavioral Sciences
Stanford University School of Medicine
To access Dr. Ostacher’s bio, please click here.
This activity is intended for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.
After completing this activity, participants should be able to:
• Identify cognitive dysfunction in patients with untreated and treated major depression by the use of screening questions and scales
• Identify the factors contributing to poor prognosis in major depressive disorder (MDD) patients, including residual symptoms
• Implement strategies to treat MDD to remission of all symptom domains
This on-demand webcast is available with synchronized slides and audio.
To be eligible for documentation of credit, participants must complete the educational activity, complete the 10-question online post-test with a score of 70% or better, and complete the evaluation form.
After successful completion of the post-test and evaluation form online, participants may immediately print their documentation of credit.
Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.
Release Date: December 9, 2014
Expiration Date: December 9, 2015
Estimated time to complete: 1.0 hour
There is no fee associated with this activity.
The evaluations are accessible via a PC (Windows 2000/XP/Vista/7) or Mac (Mac OS 10.x or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to [email protected]
This activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Global Medical Education. NACCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
NACCME designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity awards 1.0 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.0 contact hour.
North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content.
Instructional Level: Advanced
Independent Clinical Reviewer: Allan Tasman, MD, Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Schwab Endowed Chair in Psychiatry, University of Louisville School of Medicine, Louisville, Kentucky
Nurse Planner: Andrew Penn, RN, MS, NP, CNS, Psychiatric Nurse Practitioner, Kaiser Permanente, Redwood City, California; Assistant Clinical Professor, University of California, San Francisco, California
For questions regarding this educational activity, please call 609-630-6252.
The planning committee compromises Rakesh Jain, MD, MPH, Roger S. McIntyre, MD, FRCPC, Michael Ostacher, MD, MPH, MMSc, Andrew Penn, RN, MS, NP, CNS, MD, Allan Tasman, MD; Prakash Masand, MD, Global Medical Education; Raquel Gaerlan, Meaghan O’Brien, Randy Robbin, John Savage, and Jessica Steuerman, NACCME.
Financial Disclosure and Conflicts of Interest
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
The faculty have reported the following:
Dr. Jain: Consultant—Addrenex, Forest, Lilly (and spouse), Merck, Pamlab (and spouse), Pfizer, Shionogi, Shire, Sunovion; Promotional speakers bureau—Addrenex, Forest, Lilly, Merck, Pamlab, Pfizer, Shionogi, Shire, Sunovion; Grant/Research support—AstraZeneca, Forest, Lilly, Pfizer, Shire; Scientific advisor—Addrenex, Lilly, Merck, Pamlab, Pfizer, Shionogi, Shire, Sunovion
Dr. McIntyre: Advisory board—AstraZeneca, Bristol-Myers Squibb, Eli Lilly, France Foundation, GlaxoSmithKline, Janssen-Ortho, Lundbeck, Merck, Organon, Pfizer, Shire; Promotional speakers bureau—AstraZeneca, Eli Lilly, Janssen-Ortho, Lundbeck, Merck, Pfizer; CME activities—AstraZeneca, Bristol Myers-Squibb, CME Outfitters, France Foundation, Eli Lilly, I3CME, Merck, Optum Health, Pfizer, Physicians’ Postgraduate Press; Grant/Research support—AstraZeneca, Eli Lilly, Janssen-Ortho, Lundbeck, Pfizer, Shire
Dr. Masand: Consultant—Forest, Lundbeck, Merck, Pamlab, Pfizer, Sunovion, Takeda; Research support—Forest, Takeda; Promotional speakers bureau—Forest, GlaxoSmithKline, Lundbeck, Merck, Pamlab, Pfizer, Sunovion, Takeda; Stock ownership—Global Medical Education.
Dr. Ostacher: Consultant—Alexza Pharmaceuticals, Eli Lilly, Janssen, Otsuka America Pharmaceutical
Dr. Tasman and Mr. Penn have disclosed no relevant financial relationships with any commercial interests.
Ms. Gaerlan, Ms. O’Brien, Mr. Robbin, Mr. Savage, and Ms. Steuerman have disclosed no relevant financial relationships with any commercial interests.
NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.
The faculty have disclosed that the following off-label/unapproved uses of drugs and/or devices and investigational agents will be discussed in the presentations: antidepressants in the treatment of cognitive disturbances in major depression.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.
NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2014 by North American Center for Continuing Medical Education, LLC (NACCME)
All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Jointly provided by North American Center for Continuing Medical Education, LLC, an HMP Communications Holdings Company, and Global Medical Education.
Content for this session was developed by Global Medical Education.
Supported by an educational grant from Takeda Pharmaceuticals International, Inc., U.S. Region and Lundbeck Pharmaceutical Services, LLC
Dr. Ostacher is Associate Professor of Psychiatry and Behavioral Sciences at the Stanford University School of Medicine, and at the VA Palo Alto Health Care System, where he is the Associate Director of the Bipolar and Depression Research Program. After graduating with Honors in the College of Letters at Wesleyan University in Connecticut, Dr. Ostacher received his medical degree from the Vanderbilt University School of Medicine in Nashville, Tennessee. He trained in Adult Psychiatry at Harvard Medical School at The Cambridge Hospital.. He has a Masters in Public Health in Health Care Management from the Harvard University School of Public Health, and received a Masters in Medical Sciences as part of the Scholars in Clinic Science Program at Harvard Medical School.
Dr. Ostacher's major research interest is bipolar disorder and comorbid substance abuse, and received a Career Development Award from the National Institute on Alcoholism and Alcohol Abuse (NIAAA) to study substance abuse and mood while the Associate Medical Director of the Bipolar Clinic and Research Program at Massachusetts General Hospital. Dr. Ostacher won National Association for Research in Schizophrenia and Depression (NARSAD) Young Investigator Awards in 2005 and 2009 to study cognition in patients with bipolar disorder and substance abuse, and received a New Investigator Award in 2004 from the National Institute of Mental Health (NIMH), and is faculty for the University of Pittsburgh/NIMH Bipolar Career Development Institute. He was the principal investigator at MGH for BALANCE, a multinational study of maintenance treatments for bipolar disorder at Oxford University in the United Kingdom, and was the Site PI for the NIMH Bipolar Trials Network at MGH. He is an Associate Editor of Evidence-Based Mental Health and is on the editorial boards of Bipolar Disorders and the Journal of Clinical Psychiatry.
You must answer 7 questions correctly to continue.
GME and PIM are committed to excellence in continuing education, and your opinions are critical to us in this effort. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment for completing this activity.
To contact GME, email us at [email protected]